Autor(es): Kaur Parveen,Chu Justin Jang Hann

Resumo: Chikungunya virus (CHIKV) has re-emerged as a significant public health threat since the 2005 chikungunya fever epidemic in La Réunion. Driven by the medical importance of this virus, as well as the lack of approved antivirals, research into the field of CHIKV antivirals has recently intensified. Potential therapeutics that have been reported to show anti-CHIKV activity in vitro range from known broad-spectrum antivirals like chloroquine to novel strategies involving RNA silencing technology. Although most of the earlier efforts focused on compounds that target host components, some recent studies have reported viral targets such as nonstructural proteins. This article examines the reported in vitro - in vivo efficacies, as well as the therapeutic potential of these antiviral compounds.

Imprenta: Drug Discovery Today, v. 18, n. 19-20, p. 969-983, 2013

Identificador do objeto digital: 10.1016/j.drudis.2013.05.002

Descritores: Chikungunya virus - Biosynthesis ; Chikungunya virus - Proteins ; Chikungunya virus - RNA ; Chikungunya virus - Viral infections ; Chikungunya virus - Molecular methods ; Chikungunya Virus - Virus ; Chikungunya virus - Chikungunya fever ; Chikungunya virus - Epidemic ; Chikungunya virus - Public health

Data de publicação: 2013

INDICADORES

ACESSO